Yu Lingling, Chen Shengsong, Bao Hui, Zhang Weifang, Liao Minqi, Liang Qian, Cheng Xiaoshu
Department of Cardiovascular Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang of Jiangxi, 330006, China,
Department of Respiratory and Critical Care Medicine, Jiangxi Provincial People's Hospital, Nanchang of Jiangxi, 330006, China.
Onco Targets Ther. 2018 Jul 25;11:4355-4365. doi: 10.2147/OTT.S166132. eCollection 2018.
Cancer susceptibility candidate 2 (CASC2) is characterized as a tumor suppressor, which was first identified to be downregulated in endometrial carcinoma. Accumulating evidence was provided to testify the function of CASC2 in malignant tumors. However, a systematic and quantitative assessment is not available. The present study was designed to evaluate the role of CASC2 in multiple carcinomas through meta-analysis and bioinformatics.
A systematic assessment of the relationship of CASC2 with tumors was performed by using several computerized databases from inception to December 1, 2017. Pooled HR with 95% CI was calculated to summarize the effect. The data on prognosis of malignant tumors were also downloaded from The Cancer Genome Atlas (TCGA) project, OncoLnc, TANRIC and lncRNAtor database.
A total of 13 studies with 966 cancer patients were pooled in the analysis to evaluate the prognostic value of CASC2 in multiple tumors and the clinical features. The results of the meta-analysis revealed that low expression levels of CASC2 were associated with poor overall survival (OS) (pooled HR=0.39, 95% CI: 0.28-0.53, <0.0001). CASC2 obviously has a negative correlation with advanced tumor node metastasis (TNM) stage, lymph node metastasis (LNM) and T stage, respectively (<0.05). There was, however, no significant difference in gender, distant metastasis and high differentiation (>0.05). In the Kaplan-Meier curves with log-rank analysis, higher expression of CASC2 was positively correlated with longer survival time than patients with a lower level (<0.05), including kidney renal clear cell carcinoma, brain lower grade glioma, pancreatic adenocarcinoma and sarcoma.
Findings from this meta-analysis suggest that lower expression of CASC2 is associated with poorer prognosis of cancers, as well as advanced TNM, LNM and T stage. Data from the bioinformatics analysis revealed that higher expression of CASC2 was related to longer OS in patients with malignant tumors.
癌症易感性候选基因2（CASC2）被认为是一种肿瘤抑制因子，最初发现其在子宫内膜癌中表达下调。越来越多的证据证实了CASC2在恶性肿瘤中的作用。然而，目前尚无系统的定量评估。本研究旨在通过荟萃分析和生物信息学方法评估CASC2在多种癌症中的作用。
通过检索截至2017年12月1日的多个计算机化数据库，对CASC2与肿瘤的关系进行系统评估。计算合并风险比（HR）及95%可信区间（CI）以总结效应。恶性肿瘤预后数据也从癌症基因组图谱（TCGA）项目、OncoLnc、TANRIC和lncRNAtor数据库下载。
共纳入13项研究，涉及966例癌症患者，以评估CASC2在多种肿瘤中的预后价值及临床特征。荟萃分析结果显示，CASC2低表达与总体生存期（OS）较差相关（合并HR = 0.39，95% CI：0.28 - 0.53，P < 0.0001）。CASC2分别与肿瘤淋巴结转移（TNM）晚期、淋巴结转移（LNM）和T分期呈明显负相关（P < 0.05）。然而，在性别、远处转移和高分化方面无显著差异（P > 0.05）。在对数秩分析的Kaplan - Meier曲线中，CASC2高表达患者的生存时间长于低表达患者（P < 0.05），包括肾透明细胞癌、脑低级别胶质瘤、胰腺腺癌和肉瘤。
本荟萃分析结果表明，CASC2低表达与癌症预后较差以及TNM、LNM和T分期晚期相关。生物信息学分析数据显示，CASC2高表达与恶性肿瘤患者的较长OS相关。
